Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (2020 edition)

Title: Chinese Medical Association guidelines for clinical diagnosis and treatment of lung cancer (2020 edition)
Edition: Updated
Classification: Standard guideline
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users: Health care workers
Evidence classification method: Category 1 Based upon high-level evidence, there is a uniform consensus of the Expert Committee that the intervention is appropriate. Category 2A Based upon lower-level evidence, there is a uniform consensus of the Expert Committee that the intervention is appropriate. Category 2B Based upon lower-level evidence, there is a consensus of the Expert Committee that the intervention is appropriate. Category 3 Based upon any level of evidence, there is a major disagreement of the Expert Committee that the intervention is appropriate.
Development unit: 中华医学会肺癌临床诊疗指南(2020版)专家委员会
Registration time: 2021-03-23
Registration number: IPGRP-2021CN058
Purpose of the guideline: For standardizing the diagnosis and management, improving the prognosis of lung cancer, and providing authoritative guidance in screening, diagnosis, pathological typing, treatment, and follow-up of lung cancer for health workers.